TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Lumbar Interlaminar Epidural Injections in Lumbar Disc Herniation, and Discogenic Pain
Brief Summary: 1. To demonstrate clinically significant improvements in patients undergoing lumbar interlaminar epidurals. Improvement will be assessed in relation to the clinical outcome measures of pain and function.
2. To evaluate and compare the adverse event profile in all patients.


Options:
A: Arm Label: DXM 4 mg; Type: EXPERIMENTAL; Interventions: Procedure: Lumbar Transforaminal Epidural Steroid Injection | Arm Label: DXM 8 mg; Type: EXPERIMENTAL; Interventions: Procedure: Lumbar Transforaminal Epidural Steroid Injection | Arm Label: DXM 12 mg; Type: EXPERIMENTAL; Interventions: Procedure: Lumbar Transforaminal Epidural Steroid Injection | Intervention Type: PROCEDURE; Name: Lumbar Transforaminal Epidural Steroid Injection; Assigned to Arm(s): DXM 12 mg, DXM 4 mg, DXM 8 mg
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: normal saline; Assigned to Arm(s): 3
C: Arm Label: Group I; Type: OTHER; Interventions: Procedure: Lumbar Interlaminar Epidural, Procedure: Lumbar Interlaminar Epidural injection | Arm Label: Group II; Type: OTHER; Interventions: Procedure: Lumbar Interlaminar Epidural, Procedure: Lumbar Interlaminar Epidural injection | Intervention Type: PROCEDURE; Name: Lumbar Interlaminar Epidural; Assigned to Arm(s): Group I, Group II | Intervention Type: PROCEDURE; Name: Lumbar Interlaminar Epidural injection; Assigned to Arm(s): Group I, Group II
D: Arm Label: local anesthetic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Caudal epidural injection | Arm Label: Local anesthetic with generic Celestone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Caudal Epidural Injection with generic Celestone | Arm Label: Local anesthetic with Celestone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Caudal Epidural Injection with Celestone | Arm Label: Local anesthetic with DepoMedrol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Caudal Epidural Injection with DepoMedrol | Intervention Type: DRUG; Name: Caudal epidural injection; Assigned to Arm(s): local anesthetic | Intervention Type: DRUG; Name: Caudal Epidural Injection with generic Celestone; Assigned to Arm(s): Local anesthetic with generic Celestone | Intervention Type: DRUG; Name: Caudal Epidural Injection with Celestone; Assigned to Arm(s): Local anesthetic with Celestone | Intervention Type: DRUG; Name: Caudal Epidural Injection with DepoMedrol; Assigned to Arm(s): Local anesthetic with DepoMedrol

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Periodontal Therapy on Endothelial Function
Brief Summary: The purpose of this study is to determine the effect of periodontal therapy on endothelial function and other biomarkers of cardiovascular disease


Options:
A: Arm Label: Comprehensive treatment; Type: EXPERIMENTAL; Interventions: Device: Subgingival scaling and root planing | Arm Label: Community treatment; Type: OTHER; Interventions: Device: Oral prophylaxis | Intervention Type: DEVICE; Name: Subgingival scaling and root planing; Assigned to Arm(s): Comprehensive treatment | Intervention Type: DEVICE; Name: Oral prophylaxis; Assigned to Arm(s): Community treatment
B: Intervention Type: BEHAVIORAL; Name: Nutritional and life style counseling; Assigned to Arm(s): N/A
C: Arm Label: periodontal treatment; Type: EXPERIMENTAL; Interventions: Procedure: periodontal treatment | Arm Label: Control Group.; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: periodontal treatment; Assigned to Arm(s): periodontal treatment
D: Arm Label: One-Stage Full-Mouth Disinfection; Type: EXPERIMENTAL; Interventions: Procedure: One-Stage Full-Mouth Disinfection | Arm Label: Periodontal care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Periodontal care | Intervention Type: PROCEDURE; Name: One-Stage Full-Mouth Disinfection; Assigned to Arm(s): One-Stage Full-Mouth Disinfection | Intervention Type: PROCEDURE; Name: Periodontal care; Assigned to Arm(s): Periodontal care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety of Vitamin D Supplementation in the Elderly
Brief Summary: This study will evaluate the safety over 6 months of two different doses of vitamin D (cholecalciferol) in men and women age 65 and older. It will also evaluate if supplementation with vitamin D improves physical performance.


Options:
A: Arm Label: vitamin D2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D2 | Arm Label: vitamin D3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D2; Assigned to Arm(s): vitamin D2 | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D3; Assigned to Arm(s): vitamin D3
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: cholecalciferol (vitamin D) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: cholecalciferol (vitamin D) | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D); Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium and vitamin D3 supplementation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium and vitamin D3 supplementation; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: cholecalciferol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol | Arm Label: Ergocalciferol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: ergocalciferol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol; Assigned to Arm(s): cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: ergocalciferol; Assigned to Arm(s): Ergocalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.
Brief Summary: Demonstrate that the use of benchmarking improves quality of patient care, in particular the control of diabetes, lipids and blood pressure, by determining the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c 14,18, LDL-cholesterol16,18 and Systolic Blood Pressure17,18 versus control group (non-benchmarking group) after 12 months of follow-up.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Continued care; Type: EXPERIMENTAL; Interventions: Other: team-based care | Intervention Type: OTHER; Name: team-based care; Assigned to Arm(s): Continued care
B: Arm Label: access to intermediate care clinics; Type: EXPERIMENTAL; Interventions: Other: intermediate care clinics (ICCs) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: intermediate care clinics (ICCs); Assigned to Arm(s): access to intermediate care clinics
C: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A
D: Arm Label: Routine general practice care; Type: NO_INTERVENTION; Interventions: Behavioral: Structured personal care | Intervention Type: BEHAVIORAL; Name: Structured personal care; Assigned to Arm(s): Routine general practice care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.
Brief Summary: Demonstrate that the use of benchmarking improves quality of patient care, in particular the control of diabetes, lipids and blood pressure, by determining the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c 14,18, LDL-cholesterol16,18 and Systolic Blood Pressure17,18 versus control group (non-benchmarking group) after 12 months of follow-up.


Options:
A: Arm Label: Transition Coordinator; Type: OTHER; Interventions: Other: Transition Coordinator | Arm Label: Current Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Transition Coordinator; Assigned to Arm(s): Transition Coordinator
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: tailored newsletter | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: targeted newsletter | Intervention Type: BEHAVIORAL; Name: tailored newsletter; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: targeted newsletter; Assigned to Arm(s): 2
C: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A
D: Arm Label: Pt. 1 Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation | Arm Label: Pt. 1 Supportive Therapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Activation; Assigned to Arm(s): Pt. 1 Behavioral Activation | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): Pt. 1 Supportive Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Topical Application of Chlorhexidine to the Umbilical Cord for Prevention of Omphalitis and Neonatal Mortality in Rural District of Pakistan: A Community-based Randomized Control Trial
Brief Summary: The investigators hypothesize that application of 4% Chlorhexidine to the cord stump and meticulous hand washing by primary health care providers of newborn infants will reduce the incidence of Omphalitis and thereby Neonatal Mortality as compared to standardized dry cord care.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: 4% Chlorhexidine | Arm Label: B; Type: EXPERIMENTAL; Interventions: Other: Hand washing Soap | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: 4% Chlorhexidine | Arm Label: D; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 4% Chlorhexidine; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Hand washing Soap; Assigned to Arm(s): B | Intervention Type: DRUG; Name: 4% Chlorhexidine; Assigned to Arm(s): C
B: Arm Label: Chlorhexidine; Type: EXPERIMENTAL; Interventions: Procedure: Chlorhexidine vaginal and infant wash | Intervention Type: PROCEDURE; Name: Chlorhexidine vaginal and infant wash; Assigned to Arm(s): Chlorhexidine
C: Intervention Type: BEHAVIORAL; Name: Newborn Thermal Care Practice; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Newborn skin cleansing with 0.25% chlorhexidine solution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cleansing of umbilical cord with soap and water solution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cleansing of umbilical cord with 4% chlorhexidine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Topical Application of Chlorhexidine to the Umbilical Cord for Prevention of Omphalitis and Neonatal Mortality in Rural District of Pakistan: A Community-based Randomized Control Trial
Brief Summary: The investigators hypothesize that application of 4% Chlorhexidine to the cord stump and meticulous hand washing by primary health care providers of newborn infants will reduce the incidence of Omphalitis and thereby Neonatal Mortality as compared to standardized dry cord care.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: 4% Chlorhexidine | Arm Label: B; Type: EXPERIMENTAL; Interventions: Other: Hand washing Soap | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: 4% Chlorhexidine | Arm Label: D; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 4% Chlorhexidine; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Hand washing Soap; Assigned to Arm(s): B | Intervention Type: DRUG; Name: 4% Chlorhexidine; Assigned to Arm(s): C
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: CHX x 7 days | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: chx once | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dry cord care | Intervention Type: BEHAVIORAL; Name: chx once; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: CHX x 7 days; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: dry cord care; Assigned to Arm(s): 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Chlorhexidine, Procedure: Birth canal wipe | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: sterile water external genital wipe | Intervention Type: DRUG; Name: Chlorhexidine; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Birth canal wipe; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: sterile water external genital wipe; Assigned to Arm(s): 2
D: Arm Label: Chlorhexidine; Type: EXPERIMENTAL; Interventions: Procedure: Chlorhexidine vaginal and infant wash | Intervention Type: PROCEDURE; Name: Chlorhexidine vaginal and infant wash; Assigned to Arm(s): Chlorhexidine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: School Nurse-Delivered Smoking Cessation Intervention
Brief Summary: The purpose of this study is to conduct a randomized controlled school-based trial to evaluate the effectiveness of a four-session school nurse-delivered smoking cessation intervention in increasing abstinence rates among high school students who smoke.


Options:
A: Intervention Type: BEHAVIORAL; Name: Pediatric Practice-Based Smoking Intervention; Assigned to Arm(s): N/A
B: Arm Label: CI; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling Intervention | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information Intervention | Intervention Type: BEHAVIORAL; Name: Counseling Intervention; Assigned to Arm(s): CI | Intervention Type: BEHAVIORAL; Name: Information Intervention; Assigned to Arm(s): II
C: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Photoaging mobile app promoting poster campaign. | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Photoaging mobile app promoting poster campaign.; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Calfactant Therapy for Direct Acute Respiratory Distress Syndrome & Direct Acute Lung Injury in Adults and Children
Brief Summary: This study will determine if administration of an suspension of calfactant, a lung surfactant, intratracheally in patients with Direct Acute Respiratory Distress Syndrome within 48 hours of requiring mechanical ventilation can decrease the mortality in patients with lethal disease and shorten the course of respiratory failure in patients with sub-lethal disease.


Options:
A: Intervention Type: DRUG; Name: Mythylprednisolone; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: GM-CSF | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: GM-CSF; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Calfactant | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Room Air (placebo) | Intervention Type: DRUG; Name: Calfactant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Room Air (placebo); Assigned to Arm(s): 2
D: Arm Label: Albuterol Sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albuterol Sulfate, Procedure: Mini-Bronchoalveolar Lavage (BAL) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Mini-Bronchoalveolar Lavage (BAL), Drug: Placebo | Intervention Type: DRUG; Name: Albuterol Sulfate; Assigned to Arm(s): Albuterol Sulfate | Intervention Type: PROCEDURE; Name: Mini-Bronchoalveolar Lavage (BAL); Assigned to Arm(s): Albuterol Sulfate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sentinel Surveillance of Acute Malnutrition in the Region of Maradi, Niger, Children Under 5: Impact of a Preventive Intervention
Brief Summary: Malnutrition is a critical public health problem in developing countries. Malnutrition may be linked to more than one half of the deaths in children under 5 years old. In July 2001, after an intervention related to a measles epidemic, Medecins sans Frontieres-France opened a nutritional program in Maradi, in the South of Niger. The introduction of ready to use therapeutic foods (RUTF), in particular Plumpy'Nut (Nutriset, France) allowed for the treatment of the majority of children at their homes using ambulatory treatment. Children with complicated cases were cared for in an inpatient center. With ambulatory treatment the number of children cared for in the MSF program reached close to 70000 in 2006.

This study aimed to assess the effect of a 3-month distribution of RUTF in the context of a preventative supplementary feeding program. The primary hypotheses were that short-term RUTF supplementation at the village-level would prevent declines in weight-for-height and reduce the incidence of wasting in children 6 to 60 mo of age over a period of 8 mo. Because RUTF may have additional health effects, the intervention effect on height-for-age, stunting, mortality and morbidity from malaria, diarrhea, and respiratory infection were also examined.


Options:
A: Arm Label: Soy/peanut fortified spread; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Soy/peanut fortified spread | Arm Label: Milk fortified corn/soy blend; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Milk fortified corn/soy blend | Arm Label: Supplementary Plumpy®; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Supplementary Plumpy® | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy/peanut fortified spread; Assigned to Arm(s): Soy/peanut fortified spread | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk fortified corn/soy blend; Assigned to Arm(s): Milk fortified corn/soy blend | Intervention Type: DIETARY_SUPPLEMENT; Name: Supplementary Plumpy®; Assigned to Arm(s): Supplementary Plumpy®
B: Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyNut; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyDoz; Assigned to Arm(s): N/A
C: Arm Label: Current protocol; Type: ACTIVE_COMPARATOR; Interventions: Other: Current protocol | Arm Label: Integrated Protocol; Type: EXPERIMENTAL; Interventions: Other: Integrated Protocol | Intervention Type: OTHER; Name: Integrated Protocol; Assigned to Arm(s): Integrated Protocol | Intervention Type: OTHER; Name: Current protocol; Assigned to Arm(s): Current protocol
D: Intervention Type: DIETARY_SUPPLEMENT; Name: fortified spread (RUTF); Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: maize and soy flour; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BAG-RECALL Study: BIS or Anesthesia Gas to Reduce Explicit Recall
Brief Summary: The overall purpose of this study is to see if a Bispectral Index (BIS) monitor, a Food and Drug Administration (FDA) approved brain monitoring device, will help to reduce the risk of patients remembering being awake during surgery. The BIS monitor may be able to measure how asleep a patient is during surgery. Using the BIS monitor to guide anesthesia will be compared with using the concentration of anesthetic gas to guide anesthesia.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bispectral index protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: End tidal anesthetic gas-guided | Intervention Type: BEHAVIORAL; Name: Bispectral index protocol; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: End tidal anesthetic gas-guided; Assigned to Arm(s): 2
B: Arm Label: Xenon; Type: EXPERIMENTAL; Interventions: Drug: Xenon | Arm Label: Sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevoflurane | Intervention Type: DRUG; Name: Xenon; Assigned to Arm(s): Xenon | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): Sevoflurane
C: Arm Label: methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone, Placebo

Answer: A